The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).
 
Sun Young Rha
Consulting or Advisory Role - Abbvie; Daiichi Sankyo; Eisai; Ipsen; MSD Oncology; Novartis
Speakers' Bureau - Ipsen; Lilly
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Cellid; Eisai; Immunome; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Choong-Kun Lee
No Relationships to Disclose
 
Hyo Song Kim
No Relationships to Disclose
 
Beodeul Kang
No Relationships to Disclose
 
Minkyu Jung
Honoraria - Celltrion; Lilly
 
Woo Kyun Bae
No Relationships to Disclose
 
Dong-Hoe Koo
No Relationships to Disclose
 
Su-Jin Shin
No Relationships to Disclose
 
Hei-Cheul Jeung
No Relationships to Disclose
 
Dae Young Zang
No Relationships to Disclose
 
Hyun Cheol Chung
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical